Guno Sindhu Chakraborthy

Guno Sindhu Chakraborthy

Auto-generated profile, based on publicly available information

Guno Sindhu Chakraborthy

Parul Institute of Pharmacy and Research, Parul University, Limda, Waghodia, Vadodara, Gujarat 391760, India

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2017 in Synthetic Communications
Verified
Journal Article
Closed access
SASalahuddin
Salahuddin
AMA. Mazumder
A. Mazumder
MYMohammad Yar
Mohammad Yar
RMR. Mazumder
R. Mazumder
GCG. S. Chakraborthy
G. S. Chakraborthy
MRMujeeb Ur Rahman
Mujeeb Ur Rahman

7 July 2024 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
CPChaitali Palde
Chaitali Palde
TBTularam Barot
Tularam Barot
GCG. S. Chakraborthy
G. S. Chakraborthy
LPL. D. Patel
L. D. Patel
There has been a significant increase in interest in using the nasal route to administer peptides. This is mainly due to its advantages, including less invasiveness, rapid absorption, and the ability to bypass initial metabolism in the liver. The incorporation of nanotechnology has emerged as a prominent strategy, with nanocarriers such as nanoparticles and liposomes being employed to augment stability and bioavailability of peptides, as extensively discussed in this review. These carriers serve the crucial function of safeguarding peptides against enzymatic degradation while also enabling a sustained release, thus extending the therapeutic impact. Additionally, this review delves into mucoadhesive polymers and permeation enhancers, which have undergone extensive exploration to enhance nasal retention and augment the transportation of peptides across the nasal mucosa. Recent breakthroughs in nasal peptide delivery have heralded a new era in peptide-based therapies. These advancements encompass innovative formulation technologies, the utilization of nanocarriers, permeation enhancers, and the integration of intelligent materials and nasal drug delivery devices, all of which are geared towards enhancing the efficiency and efficacy of nasal peptide delivery.

1 March 2025 in Current Diabetes Reviews
Verified
Journal Article
Closed access
PDF file
SHSayan Hazra
Sayan Hazra
GCGunosindhu Chakraborthy
Gunosindhu Chakraborthy
Background: Diabetes mellitus (DM) is an autoimmune manifestation defined by persistent hyperglycemia and alterations in protein, fatty substances, and carbohydrate metabolism as an effect of problems with the secretion of insulin action or both. Manifestations include thirst, blurred eyesight, weight loss, and ketoacidosis, which can majorly lead to coma. There are different types of diabetes according to class or by cellular level. They are interrelated with hyperlipidemia as they are involved in the metabolism and regulation of physiological factors. Most parameters are seen at cellular or humoral levels, yet the underlying concern remains the same. Objective: To create a systematic correlation between the disease and locate the exact mechanism and receptors responsible for it. So, this article covers a proper way to resolve the conditions and their manifestation through literacy and diagrammatic. Conclusion: Hence, this will be an insight for many scholars to understand the exact mechanism involved in the process.

8 May 2012 in Advances in Traditional Medicine
Verified
Journal Article
Closed access
PDF file
GCGuno Sindhu Chakraborthy
Guno Sindhu Chakraborthy
VSVijay Singh
Vijay Singh
LKLalit Kumar
Lalit Kumar
RBRohan Bhadgujar
Rohan Bhadgujar

22 August 2026 in Inflammopharmacology
Verified
Journal Article
Closed access
TDThumbar Kishan Dineshbhai
Thumbar Kishan Dineshbhai
DRDhvani Rafaliya
Dhvani Rafaliya
ASAditya Singh
Aditya Singh
SMShubhrat Maheshwari
Shubhrat Maheshwari
MLManisha S Lalan
Manisha S Lalan
GCGuno Sindhu Chakraborthy
Guno Sindhu Chakraborthy

15 March 2023 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
HBHema Boddula
Hema Boddula
RSR. Shivani
R. Shivani
NSNayak S P Srinivas
Nayak S P Srinivas
JVJitendra Vaghasia
Jitendra Vaghasia
GCG. S. Chakraborthy
G. S. Chakraborthy
PGPrajwal Ghatol
Prajwal Ghatol
Sodium-glucose cotransporter-2 inhibitors, often known as SGLT2Is, are a class of medications used largely for anti-diabetic activity in oral dose form that lowers blood glucose levels. In recent years, numerous trials have documented the use of medications for conditions including renal and cardiovascular illness that go beyond only decreasing blood sugar. Other benefits of SGLT2Is' glucose-lowering activities include slowing or halting the progression of chronic kidney disease, lowering estimated glomerular filtration rate, lowering albuminuria, improving renal and cardiovascular health, and reducing estimated glomerular filtration rate. Published clinical trials reported all of these SGLT2I effects. The studies that we reviewed for this article are the Canagliflozin CardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA - CKD) trial, Effects of SGLT2I dapagliflozin on Proteinuria in Non-Diabetic Patients with The clinical studies, SGPLT2I class of medications, and their impact on cardiovascular and renal illnesses in diabetic and non-diabetic individuals are adequately covered in this review study. Keywords: SGLT2Is, Chronic kidney disease, dapagliflozin, Canagliflozin